000 01172 a2200373 4500
005 20250518032450.0
264 0 _c20200602
008 202006s 0 0 eng d
022 _a1474-5488
024 7 _a10.1016/S1470-2045(19)30156-1
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aCasasnovas, René-Olivier
245 0 0 _aPET-guided, BEACOPP
_h[electronic resource]
260 _bThe Lancet. Oncology
_c04 2019
300 _ae190 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aCyclophosphamide
650 0 4 _aHodgkin Disease
650 0 4 _aHumans
650 0 4 _aPositron-Emission Tomography
650 0 4 _aProcarbazine
650 0 4 _aVincristine
700 1 _aBouabdallah, Reda
700 1 _aBrice, Pauline
700 1 _aLazarovici, Julien
700 1 _aGhesquieres, Hervé
700 1 _aStamatoullas, Aspasia
700 1 _aBerriolo-Riedinger, Alina
700 1 _aFornecker, Luc-Matthieu
700 1 _aAndré, Marc
700 1 _aMeignan, Michel
773 0 _tThe Lancet. Oncology
_gvol. 20
_gno. 4
_gp. e190
856 4 0 _uhttps://doi.org/10.1016/S1470-2045(19)30156-1
_zAvailable from publisher's website
999 _c29546804
_d29546804